Gut microbiota manipulation through probiotics oral administration restores glucose homeostasis in a mouse model of Alzheimer’s disease


BIBLIOGRAPHIC THERAPEUTIC AGENT ANIMAL MODEL EXPERIMENTAL DESIGN OUTCOMES

Bibliographic

Year of Publication:
2020
Contact PI Name:
Laura Bonfili
Contact PI Affiliation:
School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy
Co-Authors:
Valentina Cecarini, Olee Gogoi, Sara Berardi, Silvia Scarpona, Mauro Angeletti, Giacomo Rossi, Anna Maria Eleuteri
Primary Reference (PubMED ID):
Funding Source:
Private Donation to the University of Camerino
Study Goal and Principal Findings:

Cerebral glucose homeostasis deregulation has a role in the pathogenesis and the progression of Alzheimer’s disease (AD). Current therapies delay symptoms without definitively curing AD. We have previously shown that probiotics counteract AD progression in 3xTg-AD mice modifying gut microbiota and inducing energy metabolism and glycolysis-gluconeogenesis. Ameliorated cognition is based on higher neuroprotective gut hormones concentrations, reduced amyloid-β burden, and restored proteolytic pathways. Here, we demonstrate that probiotics oral administration improves glucose uptake in 3xTg-AD mice by restoring the brain expression levels of key glucose transporters (GLUT3, GLUT1) and insulin-like growth factor receptor β, in accordance with the diminished phosphorylation of adenosine monophosphate-activated protein kinase and protein-kinase B (Akt). In parallel, phosphorylated tau aggregates decrease in treated mice. Probiotics counteract the time-dependent increase of glycated hemoglobin and the accumulation of advanced glycation end products in AD mice, consistently with memory improvement. Collectively, our data elucidate the mechanism through which gut microbiota manipulation ameliorates impaired glucose metabolism in AD, finally delaying the disease progression.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Dietary Interventions & Supplements
Therapeutic Agent:
SLAB51 Probiotic Formulation
Therapeutic Target:
Multi Target

Animal Model

Model Information:
Species:
Mouse
Model Type:
APPxPS1xTau
Strain/Genetic Background:
B6129SF2

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Histopathology
Hippocampal Atrophy
Neurofibrillary Tau Tangles
phospho-Tau
Biochemical
Advanced Glycation End Products (AGE)
AMP-Activated Protein Kinase (AMPK)
phospho-AMP-Activated Protein Kinase (phospho-AMPK)
Glucose Transporter 1 (GLUT1)
Glucose Transporter 3 (GLUT3)
Glycated Hemoglobin A1c
Insulin-Like Growth Factor 1 Receptor (IGF1R)
Protein Kinase B (Akt/PKB)
phospho-Protein Kinase B (phospho-Akt/PKB)
Total Tau Protein
phospho-Tau
Immunochemistry
Glucose Transporter 1 (GLUT1)
Glucose Transporter 3 (GLUT3)
Microscopy
Neuronal Cell Number
Neuronal Density
Toxicology
Body Weight

Source URL: http://alzped.nia.nih.gov/gut-microbiota-manipulation